Impax Investor Attys Earns $9.9M in Pricing Charges


By Katryna Perera (July 15, 2022, 9:08 p.m. EDT) — A California federal judge on Friday awarded $9.9 million in attorneys’ fees and gave final approval to a $33 million settlement that resolves the allegations that generic drug maker Impax Laboratories Inc. failed to disclose a federal investigation into possible collusive market activity.

U.S. District Judge Haywood S. Gilliam Jr. issued an order that he believes the settlement is reasonable in light of continuing litigation risks, including a pending motion to dismiss by the defendants for lack of jurisdiction in the matter .

The settlement fund represents approximately 12.5% ​​of the estimated recoverable damages at trial, according to the order, which Judge Gilliam said was in…

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of lawsuits, etc.)
  • Access to attached documents such as briefs, motions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and more!

TRY LAW360 FREE FOR SEVEN DAYS

Previous Prosecutors disavow 3 convictions in 1995 NYC subway murder
Next Pandemic snacking and drinking habits that are here to stay